{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:12:41Z","timestamp":1793506361031,"version":"4.5.0"},"reference-count":224,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The review summarizes recent advances, challenges, and future perspectives in targeted drug delivery systems (DDSs) for pancreatic cancer (PC) therapy. Given the dismal prognosis of PC treatment is hindered by a dense desmoplastic stroma, profound hypoxia, limited T-cell infiltration, and abundant immunosuppressive myeloid populations, together forming physical and immunological barriers to effective therapy. Targeted DDSs based on organic, inorganic, and biological platforms (e.g., liposomes\/lipid nanoparticles, polymeric nanoparticles, carrier-free drug self-assembly systems, hybrid inorganic\u2013organic nanomaterials, and biomimetic carriers such as exosomes and protein nanocages) can enhance tumor accumulation and reduce off-target toxicity through active ligand\u2013receptor targeting, microenvironment-adaptive delivery, and controlled release triggered by internal cues (pH, enzymes, reactive oxygen species, hypoxia) or external stimuli (light, heat, magnetic fields). Importantly, DDSs are designed to remodel the immunosuppressive tumor microenvironment (TME) by reprogramming tumor-associated macrophages, inhibiting myeloid-derived suppressor cells, activating innate immune sensing pathways, and overcoming stromal immune exclusion via stroma\u2013immune co-modulation or transcytosis-enabled penetration. We further discuss precision-medicine opportunities, proposing biomarker-guided stratification and monitoring frameworks that link patient-specific TME features (e.g., stroma-high\/immune-excluded, myeloid-dominant, weak innate priming) to rational DDS selection and combination regimens. Future development should prioritize clinically actionable combination strategies, localized\/depot delivery when appropriate, and data-driven design and optimization (including artificial intelligence and machine learning) to accelerate personalized, translatable DDSs for improving pancreatic cancer outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1785625","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:37:04Z","timestamp":1774507024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted drug delivery systems for pancreatic cancer therapy: advances, challenges, and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaonan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]},{"name":"Institute (College) of Integrative Medicine, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]},{"name":"Institute (College) of Integrative Medicine, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangshuo","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]},{"name":"Institute (College) of Integrative Medicine, Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","author":"Pourshams","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113992","article-title":"Metabolic reprogramming of immune cells in pancreatic cancer progression","volume":"157","author":"Xiang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan","year":"2020","journal-title":"Mol Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1197419","article-title":"More deaths from pancreatic cancer than breast cancer in the EU by 2017","volume":"55","author":"Ferlay","year":"2016","journal-title":"Acta Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1025618","article-title":"Nano\u2013drug delivery system for pancreatic cancer: A visualization and bibliometric analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.566216","article-title":"Overcoming drug resistance in pancreatic cancer","volume":"15","author":"Long","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210319144347","article-title":"The emerging landscapes to drug delivery systems for the treatment of pancreatic cancer","volume":"28","author":"Magri","year":"2021","journal-title":"Curr Med Chem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061231","article-title":"Gene therapy for pancreatic cancer: Specificity, issues and hopes","volume":"18","author":"Rouanet","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(82)81216-7","article-title":"Is half\u2013life of circulating liposomes determined by changes in their permeability","volume":"145","author":"Senior","year":"1982","journal-title":"FEBS Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.012070","article-title":"Lipid\u2013based drug delivery systems in cancer therapy: What is available and what is yet to come","volume":"68","author":"Yingchoncharoen","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40824-020-00190-7","article-title":"Recent advances in polymeric drug delivery systems","volume":"24","author":"Sung","year":"2020","journal-title":"Biomater Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.02.031","article-title":"Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions","volume":"332","author":"Ghezzi","year":"2021","journal-title":"J Control Release"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S335588","article-title":"Emodin\u2013conjugated PEGylation of Fe3O4 nanoparticles for FI\/MRI dual\u2013modal imaging and therapy in pancreatic cancer","volume":"16","author":"Ren","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20122988","article-title":"Targeting pancreatic cancer cells with peptide\u2013functionalized polymeric magnetic nanoparticles","volume":"20","author":"Zhu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/jz300021x","article-title":"Development of pharmaceutically adapted mesoporous silica nanoparticles platform","volume":"3","author":"Meng","year":"2012","journal-title":"J Phys Chem Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b04306","article-title":"Mesoporous silica nanoparticles with pH\u2013sensitive nanovalves for delivery of moxifloxacin provide improved treatment of lethal pneumonic tularemia","volume":"9","author":"Li","year":"2015","journal-title":"ACS Nano"},{"key":"B20","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1021\/nn3044066","article-title":"Codelivery of an optimal drug\/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2012.02.003","article-title":"Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment","volume":"38","author":"Yang","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2018.1564924","article-title":"Potential use of aptamers for diagnosis and treatment of pancreatic cancer","volume":"27","author":"Gao","year":"2019","journal-title":"J Drug Target"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115717","article-title":"Advances in targeted therapy for pancreatic cancer","volume":"168","author":"Xing","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114444","article-title":"Application of aptamer\u2013drug delivery system in the therapy of breast cancer","volume":"161","author":"Fan","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejpb.2021.02.002","article-title":"Exosomes as new therapeutic vectors for pancreatic cancer treatment","volume":"161","author":"Oliveira","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184332","article-title":"The role of exosomes in pancreatic cancer","volume":"20","author":"Lan","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000103","article-title":"Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells","volume":"33","author":"Toyoda","year":"2008","journal-title":"Int J Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303588","article-title":"Current concepts and novel targets in advanced pancreatic cancer","volume":"62","author":"Michl","year":"2013","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201200653","article-title":"Hybrid nanoparticles for detection and treatment of cancer","volume":"24","author":"Sailor","year":"2012","journal-title":"Adv Mater"},{"key":"B30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.seminoncol.2005.11.011","article-title":"Renal toxicities of chemotherapy","volume":"33","author":"de Jonge","year":"2006","journal-title":"Semin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine\u2013based therapy (NAPOLI\u20131): a global, randomised, open\u2013label, phase 3 trial","volume":"387","author":"Wang\u2013Gillam","year":"2016","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2010","article-title":"Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer","volume":"22","author":"Hingorani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.07.048","article-title":"Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation","volume":"511","author":"Rochani","year":"2016","journal-title":"Int J Pharm"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201801507","article-title":"Interventional photothermal therapy enhanced brachytherapy: A new strategy to fight deep pancreatic cancer","volume":"6","author":"Zhang","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.059","article-title":"Phase I trial of intratumoral injection of an adenovirus encoding interleukin\u201312 for advanced digestive tumors","volume":"22","author":"Sangro","year":"2004","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.228","article-title":"Advanced phase I\/II studies of targeted gene delivery in vivo: intravenous Rexin\u2013G for gemcitabine\u2013resistant metastatic pancreatic cancer","volume":"18","author":"Chawla","year":"2010","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1978.tb22035.x","article-title":"Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside","volume":"308","author":"Mayhew","year":"1978","journal-title":"Ann N Y Acad Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(76)80762-4","article-title":"Lateral diffusion rates of phosphatidylcholine in vesicle membranes: effects of cholesterol and hydrocarbon phase transitions","volume":"70","author":"Cullis","year":"1976","journal-title":"FEBS Lett"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li","year":"2019","journal-title":"Eur J Med Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.01.006","article-title":"Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside","volume":"37","author":"Yang","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02133-1","article-title":"Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma","volume":"85","author":"Brown","year":"2025","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01336-6","article-title":"Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.11.028","article-title":"Lipid-like gemcitabine diester-loaded liposomes for improved chemotherapy of pancreatic cancer","volume":"365","author":"Wang","year":"2024","journal-title":"J Control Release"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-019-0227-7","article-title":"A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability","volume":"40","author":"Li","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c02626","article-title":"Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice","volume":"16","author":"Shrestha","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03045-5","article-title":"A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models","volume":"38","author":"Matsumoto","year":"2021","journal-title":"Pharm Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902746","article-title":"MT1\u2013MMP\u2013activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy","volume":"7","author":"Wei","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41565-019-0485-z","article-title":"Enzyme\u2013activatable polymer\u2013drug conjugate augments tumour penetration and treatment efficacy","volume":"14","author":"Zhou","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-014-0113-z","article-title":"Polymeric micelles: nanocarriers for cancer\u2013targeted drug delivery","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-018-2152-3","article-title":"Strategies to improve micelle stability for drug delivery","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3273-1","article-title":"Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review","volume":"79","author":"Yousefpour Marzbali","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale\u2013up technologies: feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.08.013","article-title":"Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy","volume":"79","author":"Fan","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2012.06.007","article-title":"Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo","volume":"82","author":"Tao","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.020735","article-title":"Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice","volume":"36","author":"Reddy","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.11.081","article-title":"Self\u2013assembling methoxypoly(ethylene glycol)\u2013b\u2013poly(carbonate\u2013co\u2013L\u2013lactide) block copolymers for drug delivery","volume":"31","author":"Danquah","year":"2010","journal-title":"Biomaterials"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1021\/bc400032x","article-title":"Self\u2013assembling, amphiphilic polymer\u2013gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma","volume":"24","author":"Chitkara","year":"2013","journal-title":"Bioconjug Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.5b01419","article-title":"EGFR\u2013targeted polymeric mixed micelles carrying gemcitabine for treating pancreatic cancer","volume":"17","author":"Mondal","year":"2016","journal-title":"Biomacromolecules"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/782041","article-title":"Recent developments in nanoparticle\u2013based siRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"BioMed Res Int"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b02756","article-title":"ROS\u2013responsive polymeric micelles for triggered simultaneous delivery of PLK1 inhibitor\/miR\u201334a and effective synergistic therapy in pancreatic cancer","volume":"11","author":"Xin","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7150\/thno.24945","article-title":"Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small\u2013molecule drug in orthotopic pancreatic tumor\u2013bearing mice","volume":"8","author":"Kumar","year":"2018","journal-title":"Theranostics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28207065","article-title":"Advance progress in assembly mechanisms of carrier\u2013free nanodrugs for cancer treatment","volume":"28","author":"Zhang","year":"2023","journal-title":"Molecules"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b16209","article-title":"Self\u2013assembled gemcitabine prodrug nanoparticles show enhanced efficacy against patient\u2013derived pancreatic ductal adenocarcinoma","volume":"12","author":"Wu","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202001128","article-title":"Carrier\u2013free nanoassembly of curcumin\u2013erlotinib conjugate for cancer targeted therapy","volume":"9","author":"Cheng","year":"2020","journal-title":"Adv Healthc Mater"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120557","article-title":"Advances and perspectives in carrier\u2013free nanodrugs for cancer chemo\u2013monotherapy and combination therapy","volume":"268","author":"Huang","year":"2021","journal-title":"Biomaterials"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/nn404083m","article-title":"Two\u2013wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1021\/nn103344k","article-title":"Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase\u2013dependent macropinocytosis mechanism","volume":"5","author":"Meng","year":"2011","journal-title":"ACS Nano"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1021\/nn200809t","article-title":"Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin\u2013loaded mesoporous silica nanoparticles in a murine xenograft tumor model","volume":"5","author":"Meng","year":"2011","journal-title":"ACS Nano"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1021\/nn100690m","article-title":"Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P\u2013glycoprotein siRNA to overcome drug resistance in a cancer cell line","volume":"4","author":"Meng","year":"2010","journal-title":"ACS Nano"},{"key":"B70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1039\/c2ib20137b","article-title":"Mesoporous silica nanoparticles: A multifunctional nano therapeutic system","volume":"5","author":"Mai","year":"2013","journal-title":"Integr Biol (Camb)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.6b00941","article-title":"Functional single\u2013chain polymer nanoparticles: Targeting and imaging pancreatic tumors in vivo","volume":"17","author":"Benito","year":"2016","journal-title":"Biomacromolecules"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b00510","article-title":"Use of a lipid\u2013coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice","volume":"9","author":"Meng","year":"2015","journal-title":"ACS Nano"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2017.03.176","article-title":"Multifunctional inulin tethered silver\u2013graphene quantum dots nanotheranostic module for pancreatic cancer therapy","volume":"78","author":"Nigam Joshi","year":"2017","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202305151","article-title":"High\u2013load gemcitabine inorganic\u2013organic hybrid nanoparticles as an image\u2013guided tumor\u2013selective drug\u2013delivery system to treat pancreatic cancer","volume":"35","author":"Ischyropoulou","year":"2023","journal-title":"Adv Mater"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5b01172","article-title":"Multifunctional phosphate\u2013based inorganic\u2013organic hybrid nanoparticles","volume":"137","author":"Heck","year":"2015","journal-title":"J Am Chem Soc"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S92722","article-title":"Functionalized milk\u2013protein\u2013coated magnetic nanoparticles for MRI\u2013monitored targeted therapy of pancreatic cancer","volume":"11","author":"Huang","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"B77","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.apsb.2017.11.005","article-title":"Biomacromolecules as carriers in drug delivery and tissue engineering","volume":"8","author":"Zhang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.337","article-title":"Aptamer\u2013SH2 superbinder\u2013based targeted therapy for pancreatic ductal adenocarcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Clin Transl Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.02.011","article-title":"Milk exosomes \u2013 Natural nanoparticles for siRNA delivery","volume":"449","author":"Aqil","year":"2019","journal-title":"Cancer Lett"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1038\/s41467-019-11718-4","article-title":"Tumor exosome\u2013based nanoparticles are efficient drug carriers for chemotherapy","volume":"10","author":"Yong","year":"2019","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.07.026","article-title":"Exosomes as drug delivery systems: A brief overview and progress update","volume":"154","author":"Patil","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.06.007","article-title":"Exosome\u2013mediated small RNA delivery: A novel therapeutic approach for inflammatory lung responses","volume":"26","author":"Zhang","year":"2018","journal-title":"Mol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000875","article-title":"Exosome\u2013mediated delivery of CRISPR\/Cas9 for targeting of oncogenic KrasG12D in pancreatic cancer","volume":"4","author":"McAndrews","year":"2021","journal-title":"Life Sci Alliance"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2014.07.049","article-title":"Extracellular vesicles as drug delivery systems: Lessons from the liposome field","volume":"195","author":"van der Meel","year":"2014","journal-title":"J Control Release"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/immu.200310028","article-title":"Antigen\u2013presenting cell exosomes are protected from complement\u2013mediated lysis by expression of CD55 and CD59","volume":"33","author":"Clayton","year":"2003","journal-title":"Eur J Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1021\/ar300048p","article-title":"Lipid\u2013based nanoparticles for siRNA delivery in cancer therapy: Paradigms and challenges","volume":"45","author":"Gomes\u2013da\u2013Silva","year":"2012","journal-title":"Acc Chem Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030567","article-title":"Exosomes and the future of immunotherapy in pancreatic cancer","volume":"20","author":"Batista","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.35823","article-title":"Exosomes and pancreatic diseases: Status, challenges, and hopes","volume":"15","author":"Guo","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.02.037","article-title":"Smart exosomes enhance PDAC targeted therapy","volume":"368","author":"Creeden","year":"2024","journal-title":"J Control Release"},{"key":"B92","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14712590903321454","article-title":"Pancreatic cancer: Gene therapy approaches and gene delivery systems","volume":"10","author":"Xu","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1166\/jbn.2014.2036","article-title":"Targeted drug delivery systems for pancreatic cancer","volume":"10","author":"Khare","year":"2014","journal-title":"J BioMed Nanotechnol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i37.13343","article-title":"Gene therapy in pancreatic cancer","volume":"20","author":"Liu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04424.x","article-title":"Review article: Gene therapy, recent developments and future prospects in gastrointestinal oncology","volume":"32","author":"Touchefeu","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"B96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/1389201011314010008","article-title":"Non\u2013viral gene delivery methods","volume":"14","author":"Wang","year":"2013","journal-title":"Curr Pharm Bio\/Technol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.18.10009-10022.2004","article-title":"Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid\u2013modified adenovirus vectors in a cell\u2013type\u2013specific manner","volume":"78","author":"Shayakhmetov","year":"2004","journal-title":"J Virol"},{"key":"B98","article-title":"Factors limiting adenovirus\u2013mediated gene transfer into human lung and pancreatic cancer cell lines","volume":"5","author":"Pearson","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(02)00131-4","article-title":"The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells","volume":"38","author":"Kim","year":"2002","journal-title":"Eur J Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno\u2013associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.omtm.2017.09.006","article-title":"Safety and efficacy of AAV retrograde pancreatic ductal gene delivery in normal and pancreatic cancer mice","volume":"8","author":"Quirin","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-1192","article-title":"Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer","volume":"13","author":"Gracia-Hernandez","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0001","article-title":"Downregulation of human endogenous retrovirus type K (HERV\u2013K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/S0140-6736(15)60371-3","article-title":"Anti\u2013cancer effects of oncolytic viral therapy combined with photodynamic therapy in human pancreatic cancer cell lines","volume":"385","author":"Khaled","year":"2015","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: A phase Ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e28108","DOI":"10.1002\/jmv.28108","article-title":"VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes","volume":"95","author":"Shen","year":"2022","journal-title":"J Med Virol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.03.012","article-title":"Natural\u2013origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications","volume":"59","author":"Malafaya","year":"2007","journal-title":"Adv Drug Delivery Rev"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14011629","article-title":"Biopolymer\u2013based nanoparticles for drug\/gene delivery and tissue engineering","volume":"14","author":"Nitta","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150820101029","article-title":"Polysaccharide\u2013based nanobiomaterials as controlled release systems for tissue engineering applications","volume":"21","author":"Rodriguez\u2013Velazquez","year":"2015","journal-title":"Curr Pharm Des"},{"key":"B110","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv Drug Delivery Rev"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol Pharm"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00089","article-title":"Phase I\/II trial to evaluate the efficacy and safety of nanoparticle albumin\u2013bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2","volume":"37","author":"Macarulla","year":"2019","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.01.033","article-title":"Hyaluronic acid and albumin based nanoparticles for drug delivery","volume":"331","author":"Lei","year":"2021","journal-title":"J Control Release"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1039\/C2SM06463D","article-title":"Hyaluronic acid\u2013based hydrogels: From a natural polysaccharide to complex networks","volume":"8","author":"Xu","year":"2012","journal-title":"Soft Matter"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod67.4.1165","article-title":"Identification of hyaluronic acid\u2013binding proteins and their expressions in porcine cumulus\u2013oocyte complexes during in vitro maturation","volume":"67","author":"Yokoo","year":"2002","journal-title":"Biol Reprod"},{"key":"B116","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.colsurfb.2011.10.029","article-title":"Hyaluronic acid\u2013based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer","volume":"99","author":"Choi","year":"2012","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.09.030","article-title":"Self\u2013assembled hyaluronic acid nanoparticles for active tumor targeting","volume":"31","author":"Choi","year":"2010","journal-title":"Biomaterials"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.5b00941","article-title":"Hyaluronic acid engineered nanomicelles loaded with 3,4\u2013difluorobenzylidene curcumin for targeted killing of CD44+ stem\u2013like pancreatic cancer cells","volume":"16","author":"Kesharwani","year":"2015","journal-title":"Biomacromolecules"},{"key":"B119","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11095-020-2774-5","article-title":"Delivery of small molecule EF2 kinase inhibitor for breast and pancreatic cancer cells using hyaluronic acid based nanogels","volume":"37","author":"Comert Onder","year":"2020","journal-title":"Pharm Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.1c00267","article-title":"Ferritin: A multifunctional nanoplatform for biological detection, imaging diagnosis, and drug delivery","volume":"54","author":"Song","year":"2021","journal-title":"Acc Chem Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70444","article-title":"Ferritin\u2013based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient\u2013derived organoids: A novel approach for treatment","volume":"35","author":"Abbinantefina","year":"2026","journal-title":"Protein Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123545","article-title":"Enzyme\u2013responsive biomimetic ferritin nanoparticles for selective cancer therapy","volume":"325","author":"Hao","year":"2026","journal-title":"Biomaterials"},{"key":"B123","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13036-019-0189-9","article-title":"Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum\u20135 to solid tumors for cancer therapy","volume":"13","author":"He","year":"2019","journal-title":"J Biol Eng"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1650117","article-title":"Perineural invasion and the \u201ccold\u201d tumor microenvironment in pancreatic cancer: Mechanisms of crosstalk and therapeutic opportunities","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1585858","article-title":"Domestication and feedback: Bidirectional hijacking in pancreatic ductal adenocarcinoma microenvironment","volume":"16","author":"Qiao","year":"2025","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2025.04.007","article-title":"Tumor\u2013stromal metabolic crosstalk in pancreatic cancer","volume":"35","author":"Thakur","year":"2025","journal-title":"Trends Cell Biol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218098","article-title":"Design of nano\u2013delivery systems for pancreatic cancer immunotherapy","volume":"635","author":"Fu","year":"2025","journal-title":"Cancer Lett"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1039\/d5nr01067e","article-title":"Overcoming the tumor microenvironment in pancreatic cancer via barrier\u2013specific nanoparticle drug delivery","volume":"17","author":"Yang","year":"2025","journal-title":"Nanoscale"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115948","article-title":"Tumor microenvironment and immunometabolic reprogramming in pancreatic ductal adenocarcinoma: Barriers and breakthroughs in immunotherapy","volume":"169","author":"Xue","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.613815","article-title":"Mechanisms governing immunotherapy resistance in pancreatic ductal adenocarcinoma","volume":"11","author":"Schmiechen","year":"2020","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1717062","article-title":"Reprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer","volume":"16","author":"Hui","year":"2025","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02134-6","article-title":"Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer","volume":"26","author":"Shakiba","year":"2025","journal-title":"Nat Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI187024","article-title":"Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma","volume":"135","author":"Sun","year":"2025","journal-title":"J Clin Invest"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.605619","article-title":"Tumor\u2013derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer","volume":"11","author":"Vonderheide","year":"2020","journal-title":"Front Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-25-0251","article-title":"Myeloid\u2013derived suppressor cells: Orchestrators of tumor immune evasion and therapeutic vulnerabilities","volume":"23","author":"Wang","year":"2025","journal-title":"Mol Cancer Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid\u2013derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2401996121","article-title":"UPF1 deficiency enhances mitochondrial ROS which promotes an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma","volume":"121","author":"Su","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100587","article-title":"HIF\u20131\u03b1 regulates function and differentiation of myeloid\u2013derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J Exp Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2023.11.050","article-title":"Radiation therapy and myeloid\u2013derived suppressor cells: Breaking down their cancerous partnership","volume":"119","author":"Bergerud","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138581","article-title":"Polymorphonuclear myeloid\u2013derived suppressor cells limit antigen cross\u2013presentation by dendritic cells in cancer","volume":"5","author":"Ugolini","year":"2020","journal-title":"JCI Insight"},{"key":"B145","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid\u2013derived suppressor cells inhibit T\u2013cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582305","article-title":"Immunosuppressive tumor microenvironment in pancreatic cancer: Mechanisms and therapeutic targets","volume":"16","author":"Pan","year":"2025","journal-title":"Front Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0761-y","article-title":"Regulation and modulation of antitumor immunity in pancreatic cancer","volume":"21","author":"Leinwand","year":"2020","journal-title":"Nat Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.08.007","article-title":"A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer","volume":"169","author":"Wang","year":"2023","journal-title":"Acta Biomater"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122533","article-title":"MDSC\u2013targeting gold nanoparticles enhance PD\u20131 tumor immunotherapy by inhibiting NLRP3 inflammasomes","volume":"307","author":"Zhu","year":"2024","journal-title":"Biomaterials"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0981","article-title":"Scavenger receptor type B1 and lipoprotein nanoparticle inhibit myeloid\u2013derived suppressor cells","volume":"17","author":"Plebanek","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B151","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cytogfr.2025.06.002","article-title":"Metabolic regulation of cGAS\u2013STING signaling in the tumor microenvironment: Dual immune roles and therapeutic implications","volume":"85","author":"Wu","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"B152","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-025-01691-5","article-title":"The cGAS\u2012STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications","volume":"18","author":"Shen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9366","article-title":"Nanoparticle delivery of innate immune agonists combined with senescence\u2013inducing agents promotes T cell control of pancreatic cancer","volume":"16","author":"Chibaya","year":"2024","journal-title":"Sci Transl Med"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115596","article-title":"Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists","volume":"213","author":"Pan","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","article-title":"Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy","volume":"122","author":"Garland","year":"2022","journal-title":"Chem Rev"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500296","article-title":"STING agonists and how to reach their full potential in cancer immunotherapy","volume":"12","author":"Gehrcken","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B157","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.107837","article-title":"Identification of a novel small molecule STING agonist reshaping the immunomicroenvironment of pancreatic ductal adenocarcinoma","volume":"21","author":"Liu","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202520547","article-title":"STING agonist\u2013modified tumor targeting photosensitizer remodels cancer\u2013associated fibroblasts to potentiate photoimmunotherapy in pancreatic cancer","volume":"13","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2214278119","article-title":"Tumor\u2013targeted delivery of a STING agonist improves cancer immunotherapy","volume":"119","author":"Wu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.3c00394","article-title":"Engineering and delivery of cGAS\u2013STING immunomodulators for the immunotherapy of cancer and autoimmune diseases","volume":"56","author":"Zhou","year":"2023","journal-title":"Acc Chem Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.11.017","article-title":"Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration","volume":"330","author":"Wehbe","year":"2021","journal-title":"J\u00a0Control Release"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2025.09.004","article-title":"Extracellular matrix architecture promotes immunosuppressive microenvironments in pancreatic cancer","volume":"141","author":"Callaway","year":"2025","journal-title":"Matrix Biol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.116052","article-title":"Emerging precision drug delivery systems for controlled activation of the cGAS\u2013STING pathway in cancer, infection, and autoimmune disorders","volume":"170","author":"Pavani","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c10202","article-title":"A pH\u2013responsive and guanidinium\u2013rich nanoadjuvant efficiently delivers STING agonist for cancer immunotherapy","volume":"19","author":"Lu","year":"2025","journal-title":"ACS Nano"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c12337","article-title":"Robust and sustained STING pathway activation via hydrogel\u2013based in situ vaccination for cancer immunotherapy","volume":"18","author":"Cheng","year":"2024","journal-title":"ACS Nano"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70788","article-title":"Fibrotic fortresses and therapeutic frontiers: pancreatic stellate cells and the extracellular matrix in pancreatic cancer","volume":"14","author":"Sigirli","year":"2025","journal-title":"Cancer Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.03.002","article-title":"Fibroblasts in pancreatic cancer: molecular and clinical perspectives","volume":"29","author":"Rebelo","year":"2023","journal-title":"Trends Mol Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2972","article-title":"Prevailing role of contact guidance in intrastromal T\u2013cell trapping in human pancreatic cancer","volume":"20","author":"Hartmann","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2025.09.004","article-title":"Extracellular matrix architecture promotes immunosuppressive microenvironments in pancreatic cancer","volume":"141","author":"Callaway","year":"2025","journal-title":"Matrix Biol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123280","article-title":"Stromal fibrin shapes immune infiltration landscape of pancreatic ductal adenocarcinoma","volume":"320","author":"Karim","year":"2025","journal-title":"Biomaterials"},{"key":"B172","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41467-025-67254-x","article-title":"\u03b1PD\u20131\u2013conjugated acid\u2013cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors","volume":"17","author":"Gan","year":"2025","journal-title":"Nat Commun"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c06372","article-title":"Transcytosis\u2013triggering nanoparticles for overcoming stromal barriers and reversing immunosuppression in pancreatic cancer combinatorial therapy","volume":"25","author":"Zhang","year":"2025","journal-title":"Nano Lett"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1186\/s12967-025-07164-0","article-title":"Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells","volume":"23","author":"Zhang","year":"2025","journal-title":"J Transl Med"},{"key":"B175","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3390\/cancers13122995","article-title":"Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines","volume":"13","author":"Gorchs","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma","volume":"145","author":"Ene\u2013Obong","year":"2013","journal-title":"Gastroenterology"},{"key":"B177","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1053\/j.gastro.2024.01.028","article-title":"Transcriptomic\u2013based microenvironment classification reveals precision medicine strategies for pancreatic ductal adenocarcinoma","volume":"166","author":"George","year":"2024","journal-title":"Gastroenterology"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3401","article-title":"Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic\/predictive significance","volume":"24","author":"Wartenberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2298","article-title":"Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen","volume":"27","author":"Ogawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3141","article-title":"Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer","volume":"27","author":"V\u00e4yrynen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116685","article-title":"Breakthroughs in nanoparticle\u2013based strategies for pancreatic cancer therapy","volume":"232","author":"Escalera\u2013Anzola","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab\u2013paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S88084","article-title":"Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan","volume":"11","author":"Ko","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b09713","article-title":"What went wrong with anticancer nanomedicine design and how to make it right","volume":"14","author":"Sun","year":"2020","journal-title":"ACS Nano"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00801","article-title":"Pathophysiology\u2013driven approaches for overcoming nanomedicine resistance in pancreatic cancer","volume":"21","author":"Nair","year":"2024","journal-title":"Mol Pharm"},{"key":"B186","doi-asserted-by":"publisher","first-page":"6418","DOI":"10.1038\/s41467-022-34242-4","article-title":"Targeting vasoactive intestinal peptide\u2013mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Ravindranathan","year":"2022","journal-title":"Nat Commun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216810","article-title":"Biodistribution and therapeutic efficacy of a gold nanoparticle\u2013based targeted drug delivery system against pancreatic cancer","volume":"589","author":"Elechalawar","year":"2024","journal-title":"Cancer Lett"},{"key":"B188","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jconrel.2009.07.005","article-title":"Antitumor activity of EGFR targeted pH\u2013sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice","volume":"140","author":"Kim","year":"2009","journal-title":"J Control Release"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1323","article-title":"A targetable secreted neural protein drives pancreatic cancer metastatic colonization and HIF1\u03b1 nuclear retention","volume":"14","author":"Yamaguchi","year":"2024","journal-title":"Cancer Discov"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134924","article-title":"Construction and anti\u2013pancreatic cancer activity of selenium nanoparticles stabilized by Prunella vulgaris polysaccharide","volume":"278","author":"Zhang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201907233","article-title":"Efficient gene therapy of pancreatic cancer via a peptide nucleic acid (PNA)\u2013loaded layered double hydroxides (LDH) nanoplatform","volume":"16","author":"Yu","year":"2020","journal-title":"Small"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2023.12.166","article-title":"Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano\u2013onion (CNO)\u2013mediated delivery of gemcitabine (GEM)\u2013derived prodrugs","volume":"659","author":"Bartkowski","year":"2024","journal-title":"J Colloid Interface Sci"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123637","article-title":"Targeted delivery of genistein for pancreatic cancer treatment using hyaluronic\u2013coated cubosomes bioactivated with frankincense oil","volume":"649","author":"Sallam","year":"2024","journal-title":"Int J Pharm"},{"key":"B194","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2021.02.012","article-title":"Opportunities and delusions regarding drug delivery targeting pancreatic cancer\u2013associated fibroblasts","volume":"172","author":"Liu","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.7150\/thno.65299","article-title":"Macropinocytic dextran facilitates KRAS\u2013targeted delivery while reducing drug\u2013induced tumor immunity depletion in pancreatic cancer","volume":"12","author":"Yuan","year":"2022","journal-title":"Theranostics"},{"key":"B196","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bioactmat.2024.03.003","article-title":"Nanomaterials modulate tumor\u2013associated macrophages for the treatment of digestive system tumors","volume":"36","author":"Li","year":"2024","journal-title":"Bioact Mater"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c02626","article-title":"Gemcitabine\u2013lipid conjugate and ONC201 combination therapy effectively treats orthotopic pancreatic tumor\u2013bearing mice","volume":"16","author":"Shrestha","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01803-1","article-title":"Targeted intervention in nerve\u2013cancer crosstalk enhances pancreatic cancer chemotherapy","volume":"20","author":"Qin","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2021.102509","article-title":"Recent advances in active targeting of nanomaterials for anticancer drug delivery","volume":"296","author":"Dutta","year":"2021","journal-title":"Adv Colloid Interface Sci"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.0c00733","article-title":"Hows and whys of tumor\u2013seeking dyes","volume":"54","author":"Usama","year":"2021","journal-title":"Acc Chem Res"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1001367107","article-title":"In vivo assembly of nanoparticle components to improve targeted cancer imaging","volume":"107","author":"Perrault","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.7150\/thno.60437","article-title":"Co\u2013delivery of autophagy inhibitor and gemcitabine using a pH\u2013activatable core\u2013shell nanobomb inhibits pancreatic cancer progression and metastasis","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b03978","article-title":"Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple miRNA\/siRNA nanotherapy","volume":"14","author":"Xie","year":"2020","journal-title":"ACS Nano"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1039\/c7cs00471k","article-title":"Nanoparticle\u2013triggered in situ catalytic chemical reactions for tumour\u2013specific therapy","volume":"47","author":"Lin","year":"2018","journal-title":"Chem Soc Rev"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120139","article-title":"Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co\u2013delivery of gemcitabine and paclitaxel to pancreatic cancer cells","volume":"593","author":"Shabana","year":"2021","journal-title":"Int J Pharm"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2021.214267","article-title":"Recent advances on endogenous\/exogenous stimuli\u2013triggered nanoplatforms for enhanced chemodynamic therapy","volume":"451","author":"Sun","year":"2022","journal-title":"Coord Chem Rev"},{"key":"B208","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.biomaterials.2018.01.012","article-title":"Biomimetic and enzyme\u2013responsive dynamic hydrogels for studying cell\u2013matrix interactions in pancreatic ductal adenocarcinoma","volume":"160","author":"Liu","year":"2018","journal-title":"Biomaterials"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202203264","article-title":"In situ formed ROS\u2013responsive hydrogel with STING agonist and gemcitabine to intensify immunotherapy against pancreatic ductal adenocarcinoma","volume":"12","author":"Wang","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.05.031","article-title":"Reactive oxygen species and enzyme dual\u2013responsive biocompatible drug delivery system for targeted tumor therapy","volume":"324","author":"Zhao","year":"2020","journal-title":"J Control Release"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S466042","article-title":"Tumor cell\u2013targeting and tumor microenvironment\u2013responsive nanoplatforms for the multimodal imaging\u2013guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121582","article-title":"Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect","volume":"16","author":"Feng","year":"2024","journal-title":"Pharmaceutics"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited \u2013 Exploring the \u201cSpace","volume":"622","author":"Br\u00e4utigam","year":"2025","journal-title":"Cancer Lett"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune\u2013directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front Immunol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113824","article-title":"Biomimetic nanosystems for pancreatic cancer therapy: A review","volume":"383","author":"Pereira\u2013Silva","year":"2025","journal-title":"J Control Release"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.2024.8150","article-title":"Association of launch price and clinical value with reimbursement decisions for anticancer drugs in China","volume":"13","author":"Zhou","year":"2024","journal-title":"Int J Health Policy Manag"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2024.09.005","article-title":"Current state of nanomedicine drug products: An industry perspective","volume":"113","author":"Clogston","year":"2024","journal-title":"J Pharm Sci"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020247","article-title":"The hitchhiker\u2019s guide to human therapeutic nanoparticle development","volume":"14","author":"Ramos","year":"2022","journal-title":"Pharmaceutics"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2018.01.047","article-title":"Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities","volume":"23","author":"Agrahari","year":"2018","journal-title":"Drug Discov Today"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114357","article-title":"Nanoparticle\u2013based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment","volume":"187","author":"Tarannum","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S548825","article-title":"Strategies for pancreatic cancer\u2013responsive nanodrug platforms targeting tumor hypoxic environments","volume":"20","author":"Joo","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216979","article-title":"The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks","volume":"594","author":"Luo","year":"2024","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1785625\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T06:37:06Z","timestamp":1774507026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1785625\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":224,"alternative-id":["10.3389\/fimmu.2026.1785625"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1785625","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"article-number":"1785625"}}